BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Rating of “Moderate Buy” by Brokerages

BridgeBio Pharma, Inc. (NASDAQ:BBIO) has earned an average rating of “Moderate Buy” from the twenty-three ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and twenty have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $101.5263.

Several research analysts have issued reports on the stock. Wells Fargo & Company lifted their price target on shares of BridgeBio Pharma from $98.00 to $102.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 11th. Weiss Ratings cut BridgeBio Pharma from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Citigroup boosted their target price on BridgeBio Pharma from $82.00 to $93.00 and gave the stock a “neutral” rating in a research report on Thursday, July 16th. Bank of America upped their target price on BridgeBio Pharma from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. boosted their price objective on BridgeBio Pharma from $100.00 to $111.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th.

BridgeBio Pharma Trading Down 0.8%

Shares of NASDAQ BBIO opened at $74.84 on Friday. BridgeBio Pharma has a twelve month low of $48.78 and a twelve month high of $93.42. The company has a market capitalization of $14.63 billion, a price-to-earnings ratio of -20.96 and a beta of 0.97. The firm has a 50-day moving average of $80.74 and a two-hundred day moving average of $73.62.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.20). The firm had revenue of $243.68 million for the quarter, compared to the consensus estimate of $220.91 million. During the same quarter in the prior year, the company earned ($0.95) earnings per share. BridgeBio Pharma’s revenue was up 120.4% on a year-over-year basis. As a group, research analysts predict that BridgeBio Pharma will post -2.64 earnings per share for the current year.

Insider Activity

In other news, CAO Maricel Apuli sold 2,000 shares of the stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $80.06, for a total value of $160,120.00. Following the completion of the sale, the chief accounting officer owned 127,401 shares in the company, valued at $10,199,724.06. This represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jennifer E. Cook sold 148,589 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $88.54, for a total value of $13,156,070.06. Following the completion of the sale, the director directly owned 8,383 shares of the company’s stock, valued at approximately $742,230.82. This trade represents a 94.66% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 347,343 shares of company stock worth $27,591,000. 14.23% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BridgeBio Pharma

Institutional investors have recently bought and sold shares of the business. Silvant Capital Management LLC acquired a new position in shares of BridgeBio Pharma in the 2nd quarter valued at about $28,000. Allworth Financial LP purchased a new position in BridgeBio Pharma during the second quarter valued at approximately $31,000. Global Retirement Partners LLC grew its position in BridgeBio Pharma by 271.5% during the fourth quarter. Global Retirement Partners LLC now owns 509 shares of the company’s stock valued at $39,000 after purchasing an additional 372 shares in the last quarter. Farther Finance Advisors LLC increased its stake in BridgeBio Pharma by 91.4% in the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock valued at $39,000 after buying an additional 245 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new position in BridgeBio Pharma in the 4th quarter valued at approximately $41,000. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $120 price target, indicating that the analyst believes BridgeBio’s longer-term growth potential remains intact despite the earnings-estimate reductions. HC Wainwright Reaffirms Buy Rating for BridgeBio Pharma
• Positive Sentiment: Barclays and Cantor Fitzgerald also maintained Buy ratings on BridgeBio Pharma, providing additional analyst support for the stock. Barclays Sticks to Its Buy Rating for BridgeBio Pharma Cantor Fitzgerald Remains a Buy on BridgeBio Pharma
• Neutral Sentiment: HC Wainwright’s estimates still imply a transition from losses in 2026 to profitability in 2027, forecasting a $1.88 per-share loss for fiscal 2026 and $1.31 in earnings for fiscal 2027.
• Negative Sentiment: HC Wainwright lowered its fiscal 2026 EPS forecast to a $1.88 loss from a $1.50 loss and cut its fiscal 2027 estimate to $1.31 from $2.19. It also reduced estimates for several 2027 quarters, including Q1 to a $0.18 loss from $0.11 in earnings and Q2 to $0.19 in earnings from $0.44.
• Negative Sentiment: The estimate cuts extend to near-term results: Q3 2026 EPS was lowered to a $0.40 loss from a $0.38 loss, while Q4 2026 EPS was trimmed slightly to $0.13 from $0.14. These revisions may weigh on sentiment because they point to slower-than-previously-expected earnings progression.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.